Ramm Pharma (TSE:RAMM) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
RAMM Pharma Corp. has recently concluded a trial concerning a multimillion-dollar litigation with former CEO Sergio Martines and NATURALE SCIENCE INC, with the judge’s decision pending. The dispute involves claims and counterclaims related to contractual breaches, share purchase obligations, and fraudulent misrepresentation, with potential financial repercussions for the company’s future statements. Amidst this legal battle, RAMM continues to operate as a leader in cannabinoid pharmaceuticals, with a strong presence in Europe and a portfolio of approved products and facilities.
For further insights into TSE:RAMM stock, check out TipRanks’ Stock Analysis page.